BioSpace News Archive

QuidelOrtho Corporation announced that Douglas Bryant, President and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024, in San Francisco, CA.

Catheter Precision, Inc. announced corporate highlights of the third quarter of 2023.

Tyra Biosciences, Inc. today announced that it has initiated the SURF201 Phase 1 study of TYRA-200 and provided positive updates on its oral FGFR3-selective inhibitor, TYRA-300.

Clarity Pharmaceuticals is pleased to announce that the first patient has been dosed in its pivotal Phase III 64Cu-SAR-bisPSMA diagnostic trial in prostate cancer, CLARIFY (NCT06056830)1, at the Urology Cancer Center / XCancer Omaha, NE.

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced that the first participant has been dosed in ORION, a randomized, double-blind, placebo-controlled Phase 3 clinical trial of AMX0035.

Cyclacel Pharmaceuticals, Inc. announced today that it has entered into a definitive agreement for the purchase and sale of 388,200 shares of the Company’s common stock (or pre-funded warrants in lieu thereof) at a purchase price of $3.315 per share of common stock.

RaySearch Laboratories AB announces the launch of RayStation®* 2024A, the latest version of the company’s comprehensive treatment planning system.

Cellusion Inc., a deep tech start-up developing a novel cell therapy, announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to our regenerative medicine product “iPS cell-derived corneal endothelial cell substitute” for the treatment of bullous keratopathy.

Zealand Pharma A/S announced the submission of a New Drug Application to the US Food and Drug Administration for glepaglutide, a long-acting GLP-2 analog, for the treatment of adult patients with short bowel syndrome dependent on parenteral support.

BeiGene, Ltd. today announced the U.S. Food and Drug Administration (FDA) has approved a label update for BRUKINSA® (zanubrutinib) to include superior progression-free survival (PFS) results from the Phase 3 ALPINE trial comparing BRUKINSA against IMBRUVICA® (ibrutinib) in previously treated patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL).